Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMERICAN HOME PRODUCTS ACQUIRING CHESE-POND's HOSPITAL

Executive Summary

AMERICAN HOME PRODUCTS ACQUIRING CHESE-POND's HOSPITAL products division for $260 mil., the companies announced Sept. 17. The 45-year-old Chese-Pond's subsidiary does $100 mil. in annual sales: major products include the Kangaroo enteral feeding system, Respiradyne pulmonary function tester, Thermazene prescription burn cream and Blister Film and Co-film sterile dressings. The Chese-Pond's hospital business should blend well with American Home Products' Sherwood Medical hospital supply business. Sherwood's largest products are the Monoject line of disposable needles and syringes and the Argyle line of tubes and catheters. Commenting on the definitive agreement, American Home Products Chairman John Culligan stated that "this acquisition is an excellent fit with our Sherwood Medical Division, a leading supplier of syringes, needles, catheters and other medical devices." Chese-Pond's hospital division's sales were $84.4 mil. in 1985 and are expected to reach $100 mil. this year, based on a five-year growth rate of over 15% per annum. Net income in 1985 was $10.1 mil. In an early June announcement that the business was up for sale, Chese-Pond's Chairman Ralph Ward said "the decision to sell the division is the result of the on-going evaluation of the long-term direction of Chesebrough's business. To this extent, today's hospital products category does not meet our objectives. Revenues from the sale will be used to strengthen, via acquisition and other means, the core businesses in our Consumer Products and Chemical Products groups." Funds from the divestiture also will be used to lower debt incurred with the February 1985 acquisition of Stauffer Chemicals for $1.3 bil. In its 1985 annual report, Chese-Pond's noted that it had reduced its debt to total capital ratio from 78% immediately after the acquisition to 60.2% by the end of the year and expected to reduce the ratio to below 50% by the end of 1986. Other Chese-Pond's hospital products being picked up by American Home Products are Ballo and Faichney thermometers, Filac electronic thermometers, Intersorb and Sta-tite dressings, Magnacal, Vitaneed, Propac, Sumacal and Microlipid feeding forumulas, Thora-Drain underwater chest-drainage systems, Triflo II and Voldyne deep-breathing exercisers, Uri-Drain male incontinence devices, Vaseline and Xeroform nonadhering dressings and the Vaseline Constant Care skin care system.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel